November 2023
In November 2023, the Group defined a clear strategic direction: concentrate its research and development on minimally invasive and non-surgical medical aesthetics, narrowing its product portfolio to fillers and anti-aging products. At the same time, it began taking on customization projects for overseas clients, extending its previously domestic-focused contract manufacturing capabilities into export markets.
R&D resources were allocated around two core areas. Filler development covered hyaluronic acid, collagen and regenerative materials, with a focus on crosslinking processes, particle size control and duration of effect. Anti-aging development centered on mesotherapy combination formulations and efficacy-focused skincare, emphasizing active ingredient combinations and penetration efficiency.
For its international customization business, the Group organized delivery around the practical needs of overseas clients. Its workflow covered formulation selection and adjustment, packaging design and sampling, and the preparation of registration and technical documentation in line with the regulations of each target market. This established a customization process serving overseas brand owners and distributors.
At this stage, the Group expanded from two business lines, domestic contract manufacturing and proprietary brands, to three parallel lines: domestic contract manufacturing, proprietary brands and customization for overseas clients.